Is Sunil Healthcare overvalued or undervalued?
As of November 7, 2025, Sunil Healthcare is considered overvalued with a PE Ratio of 44.63 and an EV to EBITDA of 11.04, lagging behind peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -3.46%.
As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE Ratio of 44.63, an EV to EBITDA of 11.04, and a PEG Ratio of 0.19. These ratios suggest that the stock is priced high relative to its earnings growth potential.In comparison to its peers, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla, rated as attractive, has a PE Ratio of 22.33 and an EV to EBITDA of 5.58. These figures highlight that Sunil Healthcare is trading at a premium compared to more attractively valued competitors. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -3.46% compared to the Sensex's 6.50%. This further reinforces the view that Sunil Healthcare may be overvalued in the current market environment.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
